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INTRODUCTION
Antimicrobial resistance in Streptococcus pneumoniae has be-
come a serious concern throughout the world (1, 2). The preva-
lence of pneumococcal resistance was reported to be high in
some Asian countries, western Europe, South Africa and the
southern part of the United States (3-5). According to the in-
creasing prevalence of in vitro pneumococcal resistance, ther-
apeutic options for pneumococcal infections have been changed.
Pneumococcus is the most common cause of acute bacterial
meningitis in adults, and the mortality rate of pneumococ-
cal meningitis is as high as about 25-30% (6, 7). For pneu-
mococcal meningitis, treatment failure of a single-drug reg-
imen such as penicillin, chloramphenicol, third-generation
cephalosporins, and vancomycin has been frequently report-
ed (8-11). The combination regimen of ceftriaxone and van-
comycin or ceftriaxone plus rifampin is recommended for
empirical treatment of pneumococcal meningitis, especially
in countries with a high prevalence of resistance (12-14).
Meropenem, which has an excellent anti-pneumococcal
activity and less potential for seizure, could be one of the can-
didate regimens for pneumococcal meningitis (15). However,
there have been only a few studies on the therapeutic efficacy
of meropenem or a meropenem-based regimen in the treatment
of penicillin-resistant pneumococcal meningitis (16-19). We
have herein evaluated the therapeutic efficacy of meropenem
monotherapy and the combination of meropenem plus van-
comycin for meningitis using a rabbit model of meningitis
caused by penicillin-resistant S. pneumoniae (PRSP).
MATERIALS AND METHODS
Bacterial strain
A highly penicillin- and cephalosporin-resistant strain of
S. pneumoniae, originally isolated from a 55-yr-old Korean
patient with pneumococcal meningitis, was used in this study.
The strain was grown overnight on blood agar. The plates
were flooded with phosphate-buffered saline and aliquots of
the resultant suspension were frozen at -70℃. Aliquots were
thawed and diluted to a concentration of 5×107 cfu/mL, and
0.5 mL of this was injected intracisternally into each rabbit.
The minimum inhibitory concentrations (MICs) of antibiotics
were determined by broth microdilution with Mueller-Hin-
ton broth supplemented with 3% lysed horse blood. The min-
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Therapeutic Efficacy of Meropenem for Treatment of Experimental
Penicillin-Resistant Pneumococcal Meningitis
With the widespread emergence of antimicrobial resistance, combination regimens
of ceftriaxone and vancomycin (C+V) or ceftriaxone and rifampin (C+R) are recom-
mended for empirical treatment of pneumococcal meningitis. To evaluate the ther-
apeutic efficacy of meropenem (M), we compared various treatment regimens in a
rabbit model of meningitis caused by penicillin-resistant Streptococcus pneumoni-
ae (PRSP). Therapeutic efficacy was also evaluated by the final bacterial concen-
tration in the cerebrospinal fluid (CSF) at 24 hr. Each group consisted of six rabbits.
C+V cleared the CSF at 10 hr, but regrowth was noted in 3 rabbits at 24 hr. Meropen-
em monotherapy resulted in sterilization at 10 hr, but regrowth was observed in all
6 rabbits at 24 hr. M+V also resulted in sterilization at 10 hr, but regrowth was observ-
ed in 2 rabbits at 24 hr. M+V was superior to the meropenem monotherapy at 24
hr (reduction of 4.8 vs. 1.8 log10 cfu/mL, respectively; p=0.003). The therapeutic effi-
cacy of M+V was comparable to that of C+V (reduction of 4.8 vs. 4.0 log10 cfu/mL,
respectively; p=0.054). The meropenem monotherapy may not be a suitable choice
for PRSP meningitis, while combination of meropenem and vancomycin could be a
possible alternative in the treatment of PRSP meningitis.
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imum bactericidal concentrations (MBCs) were determined by
plating 10- L aliquots from clear microtiter wells onto blood
agar. The MICs and MBCs were as follows: penicillin 2  g/
mL and 4  g/mL, ceftriaxone 4  g/mL and 8  g/mL, van-
comycin 0.5  g/mL and 0.5  g/mL, rifampin 0.12  g/mL
and 0.25  g/mL, and meropenem 0.5  g/mL and 0.5  g/
mL, respectively (Table 1). This strain was intermediately-resis-
tant to meropenem, while it was susceptible to vancomycin
(MIC 0.5  g/mL) and rifampin (MIC 0.12  g/mL) (20).
Antimicrobial therapy
Seven treatment groups were evaluated: ceftriaxone (100
mg/kg), vancomycin (20 mg/kg), rifampin (15 mg/kg), me-
ropenem (125 mg/kg), ceftriaxone plus vancomycin, ceftri-
axone plus rifampin, and meropenem plus vancomycin. Each
antibiotic was given intravenously twice at a 5-hr interval,
except ceftriaxone which was given once. Each treatment group
consisted of six rabbits. Untreated controls (3 rabbits) received
saline alone.
Rabbit meningitis model
We used the rabbit model originally described by Dacey and
Sande (21). The study protocol was approved by the Institu-
tional Animal Care and Use Committee. Young male New
Zealand White rabbits weighing 2.5 to 3.0 kg were anesthe-
tized by intramuscular injections of ketamine (40 mg/kg) and
xylazine (15 mg/kg) and were immobilized for the induction
of meningitis and sampling of cerebrospinal fluid (CSF). An
inoculum that contained approximately 107 cfu of multidrug
resistant pneumococci was directly injected into the cisterna
magna through a spinal needle. Eighteen to twenty hours after
the intracisternal injection of the pneumococcal inoculum,
CSF was withdrawn and antimicrobial agents were adminis-
tered through a peripheral ear vein. A second dose of each
agent, except for ceftriaxone that was given once, was given
five hours later. Untreated and treated animals were euthanized
26 and 40 hr after intracisternal inoculation, respectively.
Measurement of bacterial and antibiotic concentrations
Bacterial concentrations in CSF were measured 0, 5, 10, and
24 hr after the start of antimicrobial therapy by plating undi-
luted CSF and serial 10-fold dilutions of CSF (100  L) on sheep
blood agar and incubating in 5% CO2 at 35℃for 24 hr (21).
The bacterial killing rate in the CSF was assessed by a reduc-
tion of bacterial concentrations in the CSF during the interval.
The final therapeutic efficacy of each treatment group was
assessed by the final bacterial concentrations in the CSF and
the numbers of animals surviving at 24 hr. In vivo synergism
was defined when combination therapy reduced the bacterial
concentration from the start of therapy by more than 1 log10
cfu/mL compared with the sum of the reduction with each
agent alone (21). Antibiotic concentrations were measured in
CSF sampled from treated rabbits at 60 min (peak) and 5 hr
(trough) after each antibiotic dose and in serum sampled 30
min and 5 hr after an intravenous dose. All specimens were
frozen at -70℃ until analysis. Ceftriaxone and meropenem
concentrations were determined by disk diffusion micro-bioas-
say using Escherichia coli (ATCC 10536), and the vancomycin
and rifampin concentrations were determined by disk diffu-
sion micro-bioassay using Bacillus subtilis (ATCC 6633) and
Micrococcus lutea (ATCC 9341), respectively.
Statistical analysis
The mean changes in bacterial concentrations in each treat-
ment group were compared by ANOVA (Newman-Keuls
multiple comparison test) and Tukey’s honestly significant
difference (HSD) test as a post hoc test. Mann-Whitney test
was used for comparison of two groups of results. A p value
of <0.05 was considered significant. 
RESULTS
Antibiotic concentrations
The peak antibiotic concentrations in the CSF and serum
obtained 60 min and 30 min after the initial dose of antibi-
otics, respectively and the trough concentrations obtained just
before the second dose are presented in Table 2. In regard to
meropenem a high dose (125 mg/kg) was required to main-
tain the level of CSF drug concentration compared to the usual
dose of meropenem in human, and the peak and the lowest
levels of mezopenem were 5.7 and 0.7  g/mL, respectively.
The peak CSF concentration of ceftriaxone was lower than the
Agent MIC ( g/mL) MBC ( g/mL)
Penicillin 2 4
Ceftriaxone 4 8
Vancomycin 0.5 0.5
Rifampin 0.12 0.25
Meropenem 0.5 0.5
Table 1. MICs and MBCs for the strains used in the experiments
MIC, minimum inhibitory concentration; MBC, minimum bactericidal con-
centration.
Agent
Serum
30 min 5 hr
CSF
60 min 5 hr
Ceftriaxone 120 (83.5) 41.8 (11.4) 5.2 (2.7) 7.1 (3.0)
Vancomycin 37 (12.0) 5.2 (3.3) 1.2 (1.2) 0.8 (0.3)
Rifampin 23 (3.8) 8.0 (3.8) 0.5 (0.2) 0.3 (0.2)
Meropenem 38 (22.4) 0.6 (1.2) 5.7 (4.2) 0.7 (0.6)
Table 2. Concentrations of antibiotics (mean and standard devi-
ation) in serum and CSF ( g/mL) of experimental rabbitsMeropenem for Pneumococcal Meningitis 23
MBC for the infecting strain, while peak concentrations of
vancomycin and rifampin in the CSF were three-fold and two-
fold higher than the MBC, respectively.
Therapeutic efficacy of antimicrobial regimens
CSF bacterial concentrations in each rabbit treatment group
are shown in Fig. 1, 2, 3, and 4. Meropenem resulted in ster-
ilization at 10 hr but regrowth was observed in all 6 rabbits at
24 hr (Table 3, Fig. 1). Meropenem plus vancomycin result-
ed in sterilization in all 6 rabbits at 10 hr, and regrowth was
observed in 2 rabbits at 24 hr (Table 3 and Fig. 2). Meropen-
em therapy resulted in 5 log10 cfu/mL reduction in the bacte-
rial concentration within 10 hr, but regrowth was observed
at 24 hr (Table 4 and Fig. 1). Meropenem plus vancomycin
resulted in 4.8 log10 cfu/mL reduction in the bacterial concen-
tration within 10 hr. The effect persisted until 24 hr (Table 4
and Fig. 2), but regrowth was observed in 2 rabbits (Fig. 2).
Compared with meropenem and ceftriaxone, ceftriaxone show-
ed a less reduction of bacteria at 10 hr  and at 24 hr (-1.8±
1.8 Log10 cfu/mL, mean±SD). Meropenem showed eradi-
cation of bacteria at 10 hr and reduction of bacteria at 24 hr
(-1.3±1.9 Log10 cfu/mL, mean±SD), (p=0.337 at 24 hr)
(Table 4 and Fig. 1). When meropenem or vancomycin mono-
therapy was compared with the combination of meropenem
plus vancomycin (M+V), ANOVA showed a statistically sig-
nificant difference (p=0.004), and the difference between M
+V and meropenem was significant, albeit without synergism
(reduction of 4.8 vs. 1.8 log10 cfu/mL, respectively; p=0.003),
while the difference between M+V and vancomycin was not
(p=0.181) by Tukey’s HSD test as a post hoc test (Fig. 2). Com-
pared with ceftriaxone plus vancomycin and meropenem plus
vancomycin, the combination of ceftriaxone plus vancomycin
showed -4.0±1.2 Log10 cfu/mL in CSF (mean±SD) and
meropenem plus vancomycin showed -4.8±0.4 Log10 cfu/
mL (mean±SD), (p=0.054) (Table 4, Fig. 3). Both ceftriax-
one plus vancomycin and meropenem plus vancomycin showed
eradication in all 6 rabbits at 10 hr, however, meropenem plus
vancomycin had a tendency to have superior activity against
experimental strain at 24 hr (Table 3, Fig. 3). Compared with
ceftriaxone plus vancomycin, meropenem plus vancomycin
and ceftriaxone plus rifampin, only ceftriaxone plus rifampin
showed eradication in all 6 rabbits at 24 hr (Table 3, Fig. 4).
DISCUSSION
Treatment of pneumococcal meningitis has been compli-
Treatment
group
Dose
(mg/kg)
No. of rabbits
treated
No. of rabbits with sterile CSF 
10 hr 24 hr
Untreated 3 0 -
Ceftriaxone (C) 100 6 1 0
Vancomycin (V) 20 6 5 4
Rifampin (R) 15 6 2 6
Meropenem (M) 125 6 6 0
C+V6 6 3
C+R6 4 6
M+V6 6 4
Table 3. Antibiotic regimens and sterilization effects
Treatment
group
Log10 cfu/mL in CSF, mean (SD)
0-5 hr 0-10 hr 0-24 hr
Untreated +1.3 (1.3) +0.5 (0.8) ND*
Ceftriaxone (C) -2.0 (0.9) -2.7 (2.1) -1.8 (1.8)
Vancomycin (V) -3.0 (1.0) -4.3 (0.6) -3.1 (1.9)
Rifampin (R) -1.6 (1.1) -3.2 (0.6) -4.2 (1.2)
Meropenem (M) -2.8 (0.7) -5.0 (1.4) -1.3 (1.9)
C+V -3.5 (0.9) -5.2 (1.1) -4.0 (1.2)
C+R -1.5 (0.7) -4.1 (1.6) -4.4 (1.2)
M+V -4.0 (1.5) -4.8 (0.8) -4.8 (0.4)
Table 4. Comparison of bacteriologic responses after therapy
*ND, not done; most animals died between 10 and 24 hr.
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Fig. 1. Therapeutic efficacies of ceftriaxone and meropenem by
mean bacterial concentrations in the CSF. The difference in  Log10
cfu/mL in CSF at 24 hr was not statistically significant.
Fig. 2. Therapeutic efficacies of meropenem, vancomycin, and M+
V by mean bacterial concentrations in the CSF. The difference in
Log10 cfu/mL in CSF at 24 hr between M+V and meropenem was
significant (p=0.003), but M+V and vancomycin was not signifi-
cant (p=0.181) by Tukey’s HSD test.
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cated by the emergence of in vitro pneumococcal resistance
during the past two decades. Ceftriaxone or cefotaxime can be
a drug of choice for pneumococcal meningitis by a penicillin
non-susceptible strain, if the organism is susceptible to them
(13, 14). However, therapeutic failures have been document-
ed when these agents have been used for meningitis caused
by ceftriaxone-resistant strains (MIC≥2  g/mL) (8-10, 22,
23). In our experiment, the ceftriaxone monotherapy was the
least effective regimen for the treatment of rabbit meningitis
due to PRSP. Given the strong association of ceftriaxone (or
cefotaxime) resistance with penicillin resistance among pneu-
mococci, the monotherapy of these agents is not a safe initial
choice, especially in countries where penicillin resistance is
highly prevalent. 
With the emergence of  -lactam antibiotic resistance among
pneumococci, vancomycin has assumed an important role in
the treatment of meningitis caused by strains that are not sus-
ceptible to penicillin and cefotaxime (or ceftriaxone). However,
treatment failure of vancomycin monotherapy was also report-
ed (11). The mean peak concentrations of vancomycin in the
CSF should be four- to eight-fold higher than the MBC for
sterilization of CSF in a rabbit model (24). In our model, how-
ever, the mean peak concentration of vancomycin (peak, 1.2
g/mL, trough, 0.8  g/mL) was only two-fold higher than the
MBC (0.5  g/mL) of the used strain. As a result, vancomycin
failed to sterilize the CSF in some rabbits at 24 hr, although
it showed a rapid bactericidal activity initially.
Accumulation of clinical data on treatment failures of sin-
gle-drug regimens has led to a combination of a 3rd genera-
tion cephalosporin and vancomycin or 3rd generation cepha-
losporin and rifampin as an initial empirical regimen for pneu-
mococcal meningitis (12-14). Although these combination
regimens are the standard option for treatment of bacterial
meningitis in the countries of high prevalence of PRSP, a new
option for monotherapy has been investigated.
One of the new potential options is carbapenem, which shows
an excellent in vitro activity against S. pneumoniae. However,
the clinical usefulness of imipenem-cilastatin for the treatment
of bacterial meningitis may be limited by the increased inci-
dence of drug-related seizure activity (25). On the other hand,
meropenem is considerably less likely to cause seizures (26).
Meropenem is well tolerated as either a bolus or an infusion,
and clinical trials have shown similar incidences of adverse
events to those observed with cephalosporin-based treatments.
It is well tolerated by the central nerve system (CNS), with
infrequent reports of seizures, and can therefore be used at high
doses in patients with meningitis (15). Penetration of meropen-
em into the CSF of patients with inflamed meninges is good
at a dose of 40 mg/kg in human (27). In our study, a higher
dose (125 mg/kg) of meropenem was administered to main-
tain the CSF drug level as in the previous studies (18, 19). No
significant adverse reactions were noted with this high dose.
Despite the adequate concentration of meropenem in the CSF,
meropenem monotherapy showed regrowth of bacteria at 24
hr, which suggested that meropenem had a bacteriostatic effect
on this strain. Intermediate resistance of meropenem (MIC
0.5  g/mL, MIC breakpoint; susceptible <0.25  g/mL, inter-
mediate 0.5  g/mL, resistant >1  g/mL) to the strain we used
may be the main cause of the failure in bacterial eradication.
Although the in vitro activity of meropenem against S. pneu-
moniae is excellent in general, recent reports showed an increas-
ing prevalence of isolates with a decreased susceptibility to
meropenem, especially among penicillin-resistant strains (28,
29). Given the recent epidemiologic data (28, 29) and simi-
lar results by Friedland et al. (18), meropenem monotherapy
may not be a good option for the treatment of pneumococcal
meningitis caused by resistant strains.
The therapeutic efficacy of the combination of meropenem
and vancomycin for the penicillin-resistant pneumococcal
meningitis model was recently reported by Gerber et al. who
showed no significant advantage over meropenem alone (19).
Data from our study showed that the combination of meropen-
em and vancomycin was superior to meropenem alone. But
this combination was not superior to vancomycin alone. These
Antibiotics
Control
C+V
M+V
C+R
Fig. 4. Therapeutic efficacies of C+V, M+V, and C+R by mean bac-
terial concentrations in the CSF. The difference in  Log10 cfu/mL
in CSF at 24 hr was not significant.
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Fig. 3. Therapeutic efficacies of C+V and M+V by mean bacterial
concentrations in the CSF. The difference in  Log10 cfu/mL in CSF at
24 hr was not significant (p=0.054).
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51 0 2 4findings are mainly associated with the antibiotic (meropen-
em and vancomycin) susceptibility of the strain we used. The
combination of meropenem and vancomycin was not synergis-
tic under the experimental condition.
In our model with a rifampin-susceptible strain, the com-
bination of ceftriaxone and rifampin showed a much higher
bactericidal activity than that of ceftriaxone and vancomycin
or meropenem plus vancomycin. Rifampin resistance of S.
pneumoniae may be uncommon (30). However, the bacterici-
dal effect of beta-lactam antibiotics or vancomycin was reduced
by the addition of rifampin in vitro (31). In addition, the ther-
apeutic efficacy of rifampin-based combination in the treat-
ment of pneumococcal meningitis caused by a rifampin-resis-
tant strain has not been documented. Therefore, rifampin
should be used in combination if the organism is susceptible
to rifampin or if there is a delay in the treatment response to
regimens without rifampin. 
The data from this study suggest that meropenem alone
is not effective in the treatment of pneumococcal meningi-
tis caused by a meropenem-intermediate strain. Meropenem
monotherapy may not be a suitable choice for PRSP menin-
gitis, while the combination of meropenem and vancomycin
could be a possible alternative in the treatment of PRSP menin-
gitis. The clinical usefulness of these regimens may depend
on the epidemiologic situation of meropenem resistance.
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